
RFK Jr. Overhauls Federal Autism Panel, Sparking Medical Community Backlash
Jan 29, 2026 01:35 am UTC| Health Governance
U.S. Health Secretary Robert F. Kennedy Jr. has reshaped national autism policy by appointing an entirely new slate of 21 members to the Interagency Autism Coordinating Committee (IACC), a federal panel that provides...

Sanofi Reports Positive Late-Stage Results for Amlitelimab in Eczema Treatment
Jan 23, 2026 07:26 am UTC| Business Health
Sanofi (EPA: SASY) has announced encouraging late-stage clinical trial results for its investigational drug amlitelimab, reinforcing its potential as a new treatment option for patients with moderate to severe eczema. The...

U.S. Vaccine Policy Shifts Under RFK Jr. Create Uncertainty for Pharma and Investors
Jan 22, 2026 06:25 am UTC| Governance Health Business
Sweeping changes to U.S. vaccine policy under Health Secretary Robert F. Kennedy Jr. are creating uncertainty across the pharmaceutical sector, dampening investor confidence and raising concerns among vaccine...

FDA Fast-Track Drug Reviews Delayed Over Safety and Efficacy Concerns
Jan 16, 2026 02:45 am UTC| Governance Health
The U.S. Food and Drug Administration has delayed reviews of several drugs selected for the Trump administrations new fast-track approval initiative after internal reviewers raised concerns about safety, efficacy, and...

Sanofi Gains China Approval for Myqorzo and Redemplo, Strengthening Rare Disease Portfolio
Jan 15, 2026 07:02 am UTC| Business Health Governance
Sanofi SA (EPA: SASY) has achieved a significant regulatory milestone in China after receiving approval for two of its specialty medications, Myqorzo and Redemplo. The approvals mark an important step in expanding Sanofis...

Merck Raises Growth Outlook, Targets $70 Billion Revenue From New Drugs by Mid-2030s
Jan 13, 2026 02:34 am UTC| Business Health
Merck announced on Monday that it has significantly raised its long-term growth outlook, projecting up to $70 billion in revenue from new growth drivers by the mid-2030s. The updated forecast highlights the pharmaceutical...

Viking Therapeutics Sees Growing Strategic Interest in $150 Billion Weight-Loss Drug Market
Jan 13, 2026 02:24 am UTC| Health Business
Viking Therapeutics CEO Brian Lian said pharmaceutical companies are showing broader and deeper strategic interest in weight-loss drug deals than is immediately visible, as the global obesity treatment market continues to...
Viksit Bharat 2026: Fiscal Muscle, Factory Revival, and the War on Speculation